Malignant Pancreatic Neoplasm — Trials

Malignant Pancreatic Neoplasm — Trials · CancerIndex

Clinical trials

Registered studies

3,629 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 903
Recruiting: 504
Ph III recruiting: 46
Growth YoY: +21.9%
Industry share: 32%
Top sponsor: National Cancer Institute (NCI)
Termination share: 34.5%
Trials / 1,000 deaths: 18.3 USA 2023 cdc-uscs

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (516)

clinicaltrialsPublishedShowing 151–200 of 220 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT06782932	Comparing Neoadjuvant/Adjuvant GVAX vs a mKRASvax Given With Anti-PD-1 and Anti-CD137 for Surgically Resectable Pancreatic Cancer	recruiting	Phase 1 / Phase 2	38	Sidney Kimmel Comprehensive Cancer Center at Johns HopkinsOTHER	1	Dec 3, 2025	clinicaltrials
NCT06333314	Dostarlimab for Locally Advanced or Metastatic Cancer (Non-colorectal/Non-endometrial) With Tumor dMMR/MSI(Pan-MSI-ACSE)	recruiting	Phase 2	120	UNICANCEROTHER	1